(Q41932115)

English

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer

scientific article published on May 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

author name string

M Lotem

1

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

T Peretz

2

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

O Drize

3

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Z Gimmon

4

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

D Ad El

5

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

R Weitzen

6

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

H Goldberg

7

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

I Ben David

8

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

D Prus

9

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

T Hamburger

10

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

E Shiloni

11

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

language of work or name

0 references

publication date

1 May 2002

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

86

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

10

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

1534-1539

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

1 May 2002

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600251

0 references

Autologous, hapten-modified vaccine as a treatment for human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Prognostic factors in 1,521 melanoma patients with distant metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Suppression of the responsiveness of lymphocytes from cancer patients triggered by co-culture with autologous tumor-derived cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Active-specific immunotherapy for melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Complete spontaneous regression of cutaneous primary malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

5 June 2018

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

18 August 2018

Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

18 August 2018

Antibodies to normal human melanocytes in vitiligo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746603

18 August 2018

Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant therapy of melanoma: at what cost?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognosis of skin melanoma with regional node metastases (stage II)

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of human melanoma with a hapten-modified autologous vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6600251

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41932115&oldid=1929990258"